Epidermal growth factor receptor (EGFR) mutations are major oncogenic alterations in non‐small cell lung cancer (NSCLC), particularly adenocarcinoma, and have been identified as molecular targets.1 This evidence concerns the gene EGFR and non-small cell lung carcinoma.